{"schema_version":"1","generated_at":"2026-10-29T21:16:01.449Z","data_as_of":"2026-10-26","url":"https://www.findmykol.com/kol/keith-flaherty","json_url":"https://www.findmykol.com/kol/keith-flaherty/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"keith-flaherty","name":"Keith Flaherty","credential":"MD","title":"Director of Clinical Research","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Melanoma","therapeutic_areas":["Melanoma","Lung","Gastrointestinal"],"institution":"Massachusetts General Hospital","institution_url":"https://www.findmykol.com/institution/massachusetts-general-hospital","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1861422966","orcid":"0000-0002-3402-0478","openalex":"A5023174631"},"summary":"Keith Flaherty is Director of Clinical Research at Massachusetts General Hospital. OpenAlex indexes 1,807 publications with 122,946 citations (h-index 147); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the FindMyKOL directory.","overview":{"text":"Keith Flaherty, MD, is Director of Clinical Research at Massachusetts General Hospital. The public record shows 1,807 publications with 122,946 citations (h-index 147), centered on Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 1 companies, 2 NIH-funded awards (2014–2026).","bullets":["Most recent indexed publication: 2026 · Journal of clinical oncology","Top research focus: Melanoma and MAPK Pathways","6 registered trials on ClinicalTrials.gov","Open Payments reporting from 1 companies"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Melanoma","therapeutic_area":"Oncology","trials":4,"topics":2,"strength":14},{"label":"Kidney Cancer / RCC","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":1,"topics":1,"strength":4},{"label":"Colorectal Cancer","therapeutic_area":"Oncology","trials":1,"topics":1,"strength":4},{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Prostate Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Head & Neck Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Multiple Myeloma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Glioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Endometrial Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Kidney Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Melanoma and MAPK Pathways","Cancer Immunotherapy and Biomarkers","Cutaneous Melanoma Detection and Management","Lung Cancer Treatments and Mutations","Colorectal Cancer Treatments and Studies"],"drugs_studied":{"total":1,"shown":1,"withheld":0,"rows":[{"name":"Rubraca","generic":"Rucaparib","trials":0,"payments":3,"publications":0,"mentions":3}]},"works_with":{"total":4,"shown":3,"withheld":1,"rows":[{"name":"Clovis Oncology, Inc.","trials":0,"payments":8,"mentions":8},{"name":"National Cancer Institute (NCI)","trials":4,"payments":0,"mentions":4},{"name":"Abramson Cancer Center at Penn Medicine","trials":1,"payments":0,"mentions":1}]}},"scholarship":{"works_count":1807,"cited_by_count":122946,"h_index":147,"i10_index":512,"pubmed_count":82,"latest_activity_year":2026,"citation_standing":{"top_percent":1,"cohort":"Medical Oncology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"trials":{"count":6,"shown":3,"withheld":3,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT02465060","trial_url":"https://www.findmykol.com/trial/NCT02465060"},{"nct":"NCT01611675","title":"Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma","phase":"PHASE1","status":"TERMINATED","role":"Investigator","sponsor":"Massachusetts General Hospital","source_url":"https://clinicaltrials.gov/study/NCT01611675","trial_url":"https://www.findmykol.com/trial/NCT01611675"},{"nct":"NCT00717587","title":"Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer","phase":"PHASE2","status":"UNKNOWN","role":"Investigator","sponsor":"Abramson Cancer Center at Penn Medicine","source_url":"https://clinicaltrials.gov/study/NCT00717587","trial_url":"https://www.findmykol.com/trial/NCT00717587"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":2022},"rows_total":2,"shown":2,"withheld":0,"rows":[{"payer":"Clovis Oncology, Inc.","program_year":2022,"amount_usd":48750,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1861422966"},{"payer":"Clovis Oncology, Inc.","program_year":2021,"amount_usd":257030.02,"payment_count":5,"source_url":"https://openpaymentsdata.cms.gov/search?query=1861422966"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1861422966","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cancer & immunology","share_pct":100,"classes_total":2,"classes":[{"class":"B-Raf serine-threonine kinase (BRAF) inhibitors","setting":"prescribed","share_pct":50,"drugs":[{"name":"Braftovi","share_pct":100}],"max_beneficiaries":null},{"class":"Mitogen-activated protein kinase (MEK) inhibitors","setting":"prescribed","share_pct":50,"drugs":[{"name":"Mektovi","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":2,"fiscal_years":{"first":2014,"last":2026},"rows_total":55,"shown":3,"withheld":52,"rows":[{"project":"UM1CA186709","title":"Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN","fiscal_year":2026,"amount_usd":2272446,"organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/UM1CA186709"},{"project":"UM1CA186709","title":"Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)","fiscal_year":2025,"amount_usd":2074014,"organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/UM1CA186709"},{"project":"UM1CA186709","title":"DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN","fiscal_year":2025,"amount_usd":194240,"organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/UM1CA186709"}],"source":"grants"},"congress":{"count":232,"years":{"first":2004,"last":2026},"societies":["AACR","ASCO","ASTRO","ESMO","SABCS"],"shown":3,"withheld":229,"rows":[{"title":"Comprehensive genomic profiling of matched ctDNA and tissue from patients with four common cancers enrolled to the NCI-MATCH trial.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.3045","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3045","status":"verified"},{"title":"Abstract B034: Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants","society":"AACR","meeting":"AACR Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.genfunc25-b034","source_url":"https://doi.org/10.1158/1538-7445.genfunc25-b034","status":"verified"},{"title":"Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.3006","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.3006","status":"verified"}],"source":"congress"},"publications":{"total":82,"shown":5,"withheld":77,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.","year":2026,"journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","types":["Clinical Trial, Phase III","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42585631/","status":"verified"},{"title":"ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42578969/","status":"verified"},{"title":"Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay.","year":2026,"journal":"JCO precision oncology","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42566732/","status":"verified"},{"title":"Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.","year":2026,"journal":"Nature communications","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42342704/","status":"verified"},{"title":"Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.","year":2026,"journal":"JCO precision oncology","types":["Journal Article","Clinical Trial, Phase II"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42308463/","status":"verified"}],"most_cited":{"total":1807,"shown":5,"withheld":1802,"rows":[{"title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","year":2011,"cited_by_count":7722,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1103782"},{"title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","year":2016,"cited_by_count":4926,"type":"article","source_url":"https://doi.org/10.1126/science.aad0501"},{"title":"Final Version of 2009 AJCC Melanoma Staging and Classification","year":2009,"cited_by_count":4608,"type":"article","source_url":"https://doi.org/10.1200/jco.2009.23.4799"},{"title":"Inhibition of Mutated, Activated BRAF in Metastatic Melanoma","year":2010,"cited_by_count":3564,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1002011"},{"title":"Genomic Classification of Cutaneous Melanoma","year":2015,"cited_by_count":3144,"type":"article","source_url":"https://doi.org/10.1016/j.cell.2015.05.044"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Dennie Tompers Frederick","coauthored_works":411},{"name":"Meenhard Herlyn","coauthored_works":300},{"name":"Jennifer Ann Wargo","coauthored_works":242}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/keith-flaherty-md","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":2,"shown":2,"rows":[{"value":"MD, Johns Hopkins University School of Medicine","source_url":"https://www.massgeneral.org/doctors/doctor.aspx?id=18371","status":"provisional","collected_at":"2026-10-28"},{"value":"Board certification: Medical Oncology, American Board of Internal Medicine","source_url":"https://www.massgeneral.org/doctors/doctor.aspx?id=18371","status":"provisional","collected_at":"2026-10-28"}]},"roles":{"total":7,"shown":3,"rows":[{"value":"President, AACR (2026-2027)","source_url":"https://www.aacr.org/governance/keith-t-flaherty-md/","status":"verified","collected_at":"2026-10-28"},{"value":"President-Elect, AACR (2025-2026)","source_url":"https://www.aacr.org/?p=722353","status":"provisional","collected_at":"2026-10-28"},{"value":"Editor-in-Chief, Clinical Cancer Research (2016-2025)","source_url":"https://www.aacr.org/governance/keith-t-flaherty-md/","status":"verified","collected_at":"2026-10-28"}]},"awards":{"total":5,"shown":3,"rows":[{"value":"OncLive Giants of Cancer Care Award for Melanoma (2020)","source_url":"https://www.aacr.org/governance/keith-t-flaherty-md/","status":"verified","collected_at":"2026-10-28"},{"value":"Society for Melanoma Research Lifetime Achievement Award (2019)","source_url":"https://www.aacr.org/governance/keith-t-flaherty-md/","status":"verified","collected_at":"2026-10-28"},{"value":"National Cancer Institute Michaele C. Christian Oncology Development Lectureship and Award (2015)","source_url":"https://www.aacr.org/governance/keith-t-flaherty-md/","status":"verified","collected_at":"2026-10-28"}]},"secondary_affiliations":{"total":3,"shown":3,"rows":[{"value":"Professor of Medicine, Harvard Medical School","source_url":"https://www.aacr.org/governance/keith-t-flaherty-md/","status":"verified","collected_at":"2026-10-28"},{"value":"Associate member, Broad Institute of MIT and Harvard","source_url":"https://www.aacr.org/governance/keith-t-flaherty-md/","status":"verified","collected_at":"2026-10-28"},{"value":"Founding member, Mass General Brigham","source_url":"https://www.aacr.org/governance/keith-t-flaherty-md/","status":"verified","collected_at":"2026-10-28"}]},"media":{"total":2,"shown":2,"rows":[{"value":"PEGS-The Chain Episode 74 (interview, June 2025)","source_url":"https://www.healthtech.com/the-chain/keith-flaherty-president-elect-of-aacr-on-public-and-private-collabs-ai-optimism-and-more","status":"provisional","collected_at":"2026-10-28"},{"value":"Podcast: \"Melanoma is Becoming Easier to Treat\" (AI and Healthcare podcast, 2022)","source_url":"https://mtrudnak.podbean.com/e/melanoma-is-becoming-easier-to-treat","status":"provisional","collected_at":"2026-10-28"}]}},"similar":[{"name":"James Januzzi","slug":"james-januzzi","institution":"Massachusetts General Hospital","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/james-januzzi","json_url":"https://www.findmykol.com/kol/james-januzzi/profile.json"},{"name":"Maurizio Fava","slug":"maurizio-fava","institution":"Massachusetts General Hospital","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/maurizio-fava","json_url":"https://www.findmykol.com/kol/maurizio-fava/profile.json"},{"name":"Steven Greenberg","slug":"steven-greenberg","institution":"Massachusetts General Hospital","specialty":"Neurology","url":"https://www.findmykol.com/kol/steven-greenberg","json_url":"https://www.findmykol.com/kol/steven-greenberg/profile.json"},{"name":"Andrew Zhu","slug":"andrew-zhu","institution":"Massachusetts General Hospital","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/andrew-zhu","json_url":"https://www.findmykol.com/kol/andrew-zhu/profile.json"},{"name":"Jedd Wolchok","slug":"jedd-wolchok","institution":"Weill Cornell Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jedd-wolchok","json_url":"https://www.findmykol.com/kol/jedd-wolchok/profile.json"},{"name":"Frank Hodi","slug":"frank-hodi","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/frank-hodi","json_url":"https://www.findmykol.com/kol/frank-hodi/profile.json"},{"name":"Omid Hamid","slug":"omid-hamid","institution":"The Angeles Clinic and Research Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/omid-hamid","json_url":"https://www.findmykol.com/kol/omid-hamid/profile.json"},{"name":"Walter Urba","slug":"walter-urba","institution":"Providence Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/walter-urba","json_url":"https://www.findmykol.com/kol/walter-urba/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":3,"funding":52,"congress":229,"publications":77,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2022","collected_at":"2026-10-28"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-10-28"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-28"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}